Laverock TherapeuticsBritish targeted gene silencing specialist Laverock Therapeutics Ltd has expanded its seed funding to £20m by a new financing round led by xx and xx. The company said it will use the funds to…l
Tag Archive for: miRNA
uniqure NVAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.